Reducing residual ASCVD risk with LDL-C lowering therapies: Why the urgency beyond the ACS emergency?

Sponsored by Sanofi Australia Pty Ltd

A recent sponsored educational meeting provided insights into the best-practice timeframe for initiating early intensive lipid-lowering therapy and its impact  on the risk of major adverse cardiovascular events (MACE). It featured discussion by renowned Cardiologist Professor Shaun Goodman, Associate Head in the Division of Cardiology, Department of Medicine, at St. Michael’s Hospital and University of ...

Already a member?

Login to keep reading.

© 2021 the limbic